scholarly journals Antimicrobial Dosing Error in Intermittent & Continuous Hemodialysis

2021 ◽  
Vol 2 (3) ◽  
pp. 8-9
Author(s):  
Saja M Alhabardi ◽  
◽  
Maha Almoliki ◽  
Albatoul Almeshari ◽  
Maha Alammari ◽  
...  
Keyword(s):  
Hemodialysis Patient ◽  
Immunocompromised Patient ◽  
Epidemiological Studies ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Dosing Error ◽  
Antibiotic Drugs ◽  
Life Saving ◽  
Stage Renal Disease ◽  
End Stage ◽  
Continuous Hemodialysis

Antibiotic drugs are the most frequently prescribed medications among hospitalized patients for life-saving purposes, mainly in immunocompromised patient, like in patient with end stage renal disease on hemodialysis (HD) or those who had documented bacterial infection. Antibiotics disposition and their pharmacokinetics and pharmacodynamics properties are affected in hemodialysis patient which increases the number of antibiotics dosing errors. Several epidemiological studies found that the majority of medication error related to antibiotics occurred during the prescribing phase (30.8%). However, there is missing data about the prevalence of errors in antibiotics dosing in HD patients.

scholarly journals Erythropoietin-Resistant Anemia Secondary to Zinc-Induced Hypocupremia in a Hemodialysis Patient

2021 ◽  
pp. 167-175
Author(s):  
Stephanie Munie ◽  
Pairach Pintavorn
Keyword(s):  
Copper Deficiency ◽  
Hemodialysis Patient ◽  
Esrd Patient ◽  
Serological Testing ◽  
Zinc Supplement ◽  
Excessive Intake ◽  
Stage Renal Disease ◽  
End Stage ◽  
Work Up ◽  
Excess Zinc

Excessive intake of zinc is a known but often forgotten cause of copper deficiency, and its consequences in the context of end-stage renal disease (ESRD) are not widely discussed. Zinc-induced copper deficiency (ZICD) can result in erythropoietin (EPO)-resistant anemia and may not be considered as a possible etiology when conducting the work-up. We present a case wherein an ESRD patient had been receiving excess zinc for several months and subsequently experienced EPO-resistant anemia. Our patient’s GI work-up was negative, and increased doses of iron and EPO-stimulating agent were ineffective. She underwent a bone marrow biopsy and more serological testing. She was ultimately diagnosed with ZICD, and cessation of her zinc supplement and initiation of copper replacement proved effective in restoring EPO responsiveness. Awareness of ZICD as a possible factor in EPO-resistant anemia could lead to an expedited diagnosis and avoid an unnecessary and extensive work-up.

scholarly journals Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases

Pharmacy ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 59
Author(s):  
Soo Min Jang ◽  
Smitha Anam ◽  
Tara Pringle ◽  
Paul Lahren ◽  
Sergio Infante
Keyword(s):  
Calcium Release ◽  
Hemodialysis Patient ◽  
Compensatory Mechanism ◽  
Normal Range ◽  
Mineral And Bone Disorder ◽  
Bone Disorder ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients ◽  
Pth Level

A common complication of end-stage renal disease (ESRD) is mineral and bone disorder. Yet, many anti-osteoporotic drugs are contraindicated in ESRD patients. Denosumab, a monoclonal antibody, does not require renal dose adjustment. However, its use is uncertain due to a lack of safety and efficacy of data in this population. Two hemodialysis patient cases of contrasting responses in parathyroid hormone (PTH) after denosumab administration were observed. Patient 1, a 62-years-old male received denosumab 60 mg at Day 0. His calcium decreased from 8.8 mg/dL to 6.8 mg/dL on Day 30. The PTH level increased from 265 pg/mL to 372 pg/mL after 30 days. Calcium and PTH levels approached normal range after increasing doses of vitamin D/calcium supplements, and calcitriol. Patient 2, a 72-years-old male on hemodialysis also received denosumab 60 mg on Day 0. His baseline calcium and PTH were 9.2 mg/dL and 420 pg/mL, respectively. On Day 30, his calcium level decreased (6.8 mg/dL) but, PTH level drastically increased (>5000 pg/mL). Denosumab commonly causes hypocalcemia and hyperparathyroidism since it inhibits osteoclast activation, reduces calcium release from bone and increases PTH levels as a compensatory mechanism. With a wait-and-watch approach, Patient 2’s levels approached the normal range (calcium 9.6 mg/dL and PTH 274 pg/mL at Day 90).

scholarly journals Premature atherosclerosis and acute coronary syndrome in a child with end-stage renal disease

2021 ◽  
Vol 69 (1) ◽  
Author(s):  
Tülay Becerir ◽  
Münevver Yılmaz ◽  
İlknur Girişgen ◽  
Neslihan Yılmaz ◽  
Dolunay Gürses ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Left Coronary Artery ◽  
Premature Atherosclerosis ◽  
Case Presentation ◽  
Coronary Syndrome ◽  
Life Saving ◽  
Stage Renal Disease ◽  
End Stage

Abstract Background Although acute coronary syndrome is rare in children, it is the most important cause of mortality in children with end-stage renal disease. Case presentation Here, a 16-year-old pediatric patient, who has been on dialysis since the age of 3, and who was diagnosed with acute coronary syndrome and placed an emergency percutaneous transcatheter stent in the left anterior descending branch of the left coronary artery is presented. It is important that the present patient does not have any electrocardiography findings in favor of cardiovascular disease and that he cannot fully explain the complaint of chest pain due to his mental retardation. Conclusions Early detection of acute coronary syndrome is life-saving, especially in children with chronic kidney disease.

scholarly journals Catheter-Related ESBL-Producing Leclercia adecarboxylata Septicemia in Hemodialysis Patient: An Emerging Pathogen?

2020 ◽  
Vol 2020 ◽  
pp. 1-3 ◽  
Author(s):  
Roaa Sultan Alosaimi ◽  
Mai Muhmmed kaaki
Keyword(s):  
End Stage Renal Disease ◽  
Hemodialysis Patient ◽  
Multidrug Resistant ◽  
Beta Lactamase ◽  
Emerging Pathogen ◽  
First Case ◽  
Stage Renal Disease ◽  
End Stage ◽  
Multidrug Resistant Strain ◽  
Producer Strains

We report a multidrug-resistant strain of Leclercia adecarboxylata which was responsible for a catheter-related bacteremia, in a 50-year-old female with an end-stage renal disease on hemodialysis. The isolated strain was an extended beta-lactamase producer. Based on a literature review of L. adecarboxylata, there have been only two reports of extended beta-lactamase producer strains. To our knowledge, this is the first case reported in Saudi Arabia.

scholarly journals Late diagnosis of Fabry Disease in hemodialysis patient

2019 ◽  
pp. 48-53
Author(s):  
S. Fomina ◽  
O. Ovska
Keyword(s):  
Renal Disease ◽  
Fabry Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patient ◽  
Late Diagnosis ◽  
Medical Community ◽  
Clinical Criteria ◽  
Lysosomal Disorders ◽  
Stage Renal Disease ◽  
End Stage

The Fabry Disease in young white man with End Stage Renal Disease was reported. Diagnosis was detected at stage of hemodialysis treatment despite sings which admitted as clinical criteria were found at childhood but did not identify during 20 years due limited awareness of medical community about lysosomal disorders.

scholarly journals Clinical correlates of the restless legs syndrome

2012 ◽  
Vol 70 (7) ◽  
pp. 529-531 ◽  
Author(s):  
Luis Fabiano Marin ◽  
Andre Carvalho Felicio ◽  
William Adolfo Santos ◽  
Lucila Bizari Prado ◽  
Gilmar Fernandes Prado
Keyword(s):  
Restless Legs Syndrome ◽  
Treatment Options ◽  
Disease Onset ◽  
Epidemiological Studies ◽  
Deficiency Anemia ◽  
Clinical Correlates ◽  
Restless Legs ◽  
Male Sex ◽  
Stage Renal Disease ◽  
End Stage

OBJECTIVE: To determine the clinical correlates of the restless legs syndrome (RLS) in a Brazilian sleep disorders center. METHODS: We retrospectively studied 118 patients with RLS from January, 2004, to December, 2010. The analyzed variables were: age at disease onset, gender, race, years of school instruction, primary and secondary RLS, and treatment options. RESULTS: Among the studied patients, 83.9% were women with a female/male sex ratio of 5:1. Mean age of the patients at symptom onset ± standard deviation was 41.7±17.9 years-old. The primary RLS was found in 85% of patients. The other 15% remainders consisted of secondary forms, and they were associated with neuropathy, iron deficiency anemia, end-stage renal disease, or Parkinson's disease. Drug therapy for RLS was introduced in 67% of patients. CONCLUSIONS: Most patients presented primary RLS with an early disease onset. Further epidemiological studies are welcomed to provide better information on secondary RLS in Brazil.

FEASIBILITY OF SMART HEMODIALYSIS PATIENT CARE USING SENSORS EMBEDDED IN PERSONALIZED 3D PRINTING CAST

2019 ◽  
Vol 19 (02) ◽  
pp. 1940017
Author(s):  
WEI-LING CHEN ◽  
TSUNG-LUNG YANG ◽  
PO-LEI LEE ◽  
CHUNG-DANN KAN
Keyword(s):  
Patient Care ◽  
Hemodialysis Patient ◽  
The United States ◽  
Annual Data ◽  
Dialysis Access ◽  
Frequency Spectra ◽  
Content Index ◽  
The Status ◽  
Stage Renal Disease ◽  
End Stage

The ever-increasing incidence of end-stage renal disease (ESRD) has already become a major burden to health budgets and a threat to public health nationwide in Taiwan. According to the United States Renal Data System Annual Data Report in 2015, the prevalence and incidence of ESRD in Taiwan are the highest in the world. Moreover, for the population of 82 thousand ESRD patients receiving hemodialysis treatments, the total cost is up to NT$34.2 billion annually out of the National Health Insurance (NHI) program budget. This project is to design a wearable medical device which can measure and monitor the fluid dynamics of the dialysis access using sensor of phonoangiography (PAG) for exploring vascular pitch pattern and sensor of Photoplethysmography (PPG) for estimating the flow volume as a double checking of the AV access condition. We use arteriovenous access (AVA) stenosis detector based on phonoangiography technique and autoregressive model to detect access stenosis and simultaneously estimate the status of AVA life cycle by tracking and obtaining changes in frequency spectra domain. It helps hemodialysis patients to be aware earlier of the dysfunction of AVA and reminds them to make a return visit. The purpose of the complement deployment of vital sign sensors is to improve the prognosis and optimize overall health by providing analysis of physiological signals, including water content index, pulse oximetry, and blood pressure at the same time. With these sensors, the concept of holistic hemodialysis patient care (HHPC) might be proved.

scholarly journals Vancomycin Induced Thrombocytopenia – Protracted Course in a Hemodialysis Patient

2019 ◽  
Vol 12 (3) ◽  
pp. 749-754 ◽  
Author(s):  
Nisha Elizabeth Ajit ◽  
Sindhu Priya Devarashetty ◽  
Samip Master
Keyword(s):  
Renal Disease ◽  
Renal Clearance ◽  
End Stage Renal Disease ◽  
Side Effect ◽  
Hemodialysis Patient ◽  
Treatment Modalities ◽  
Platelet Destruction ◽  
Life Threatening ◽  
Stage Renal Disease ◽  
End Stage

Vancomycin induced thrombocytopenia (VIT) is an uncommon side effect of vancomycin which can manifest from mild petechiae to life-threatening bleed. Decreased renal clearance of vancomycin results in prolonged thrombocytopenia by antibody-mediated platelet destruction in the presence of vancomycin. Improvement in thrombocytopenia is achieved with the elimination of vancomycin. We describe a patient with end stage renal disease who experienced a protracted course of thrombocytopenia from vancomycin. We illustrate the mechanism of thrombocytopenia and the treatment modalities used by us and those described in literature. VIT is an important differential in patients with thrombocytopenia admitted to the hospital.

scholarly journals An Intact Dopamine Sensitivity in the Brain: A Necessity to Recover Hyperprolactinemia and Galactorrhea in a Female Hemodialysis Patient?

2017 ◽  
Vol 2017 ◽  
pp. 1-3
Author(s):  
Eva Philipse ◽  
Ester Philipse ◽  
Theodorus Twickler ◽  
Amaryllis Van Craenenbroeck ◽  
Marie Madeleine Couttenye ◽  
...  
Keyword(s):  
Hemodialysis Patient ◽  
Treatment Strategies ◽  
Hemodialysis Patients ◽  
Prolactin Secretion ◽  
Subsequent Treatment ◽  
Dialysis Session ◽  
Single Session ◽  
Stage Renal Disease ◽  
End Stage ◽  
The Brain

A female hemodialysis patient with galactorrhea due to hyperprolactinemia was treated with different dialysis modalities to assess the effect on prolactin levels. A single session of both high-flux hemodialysis and hemodiafiltration resulted in decreased prolactin levels (16,6% and 77,2%, resp.). However, baseline prolactin levels measured immediately before the next dialysis session did not change markedly. After cabergoline treatment was started, prolactin levels normalized and galactorrhea disappeared. Thus, dopaminergic inhibition of prolactin secretion might be reduced in patients with end-stage renal disease. This dopaminergic resistance could be an important mechanism of hyperprolactinemia in hemodialysis patients and its subsequent treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document